Analysis of myeloid, B-cell, and NK-cell populations in STI-571–treated tumor-bearing mice
. | NK1.1+, % . | CD11b+, % . | CD11c+, % . | B220, % . |
|---|---|---|---|---|
| No treatment | 0.9 ± 0.2 | 3.8 ± 0.3 | 2.2 ± 0.1 | 72.7 ± 3.0 |
| STI-571, 12.5 mg/kg | 1.3 ± 0.2 | 4.2 ± 0.2 | 1.8 ± 0.1 | 70.7 ± 3.5 |
| Vaccine, 1 × 107 pfu | 0.6 ± 0.2 | 5.9 ± 0.3 | 2.2 ± 0.3 | 67.4 ± 2.6 |
| Vaccine + STI-571 | 1.8 ± 0.1 | 7.7 ± 0.4 | 2.7 ± 0.4 | 68.6 ± 1.3 |
. | NK1.1+, % . | CD11b+, % . | CD11c+, % . | B220, % . |
|---|---|---|---|---|
| No treatment | 0.9 ± 0.2 | 3.8 ± 0.3 | 2.2 ± 0.1 | 72.7 ± 3.0 |
| STI-571, 12.5 mg/kg | 1.3 ± 0.2 | 4.2 ± 0.2 | 1.8 ± 0.1 | 70.7 ± 3.5 |
| Vaccine, 1 × 107 pfu | 0.6 ± 0.2 | 5.9 ± 0.3 | 2.2 ± 0.3 | 67.4 ± 2.6 |
| Vaccine + STI-571 | 1.8 ± 0.1 | 7.7 ± 0.4 | 2.7 ± 0.4 | 68.6 ± 1.3 |
BALB/c mice were injected intravenously with 1 × 106 A20HA tumor cells on day - 10. From day - 9 to day 0, half of the mice received intraperitoneal injection of STI-571 (12.5 mg/kg per day) or vehicle alone. On day zero, all the mice received 2.5 × 106 anti-HA TCR+ transgenic CD4+ T cells intravenously. On day +9, mice were immunized subcutaneously with 1 × 107 pfu vacc-HA. Animals were killed 6 days later (day + 15) and their spleens were harvested. Splenocytes were then stained with antibodies against NK1.1, CD11b, CD11c, and B220 as indicated in “Materials and methods.” Values are the mean ± SE from 4 mice in each group.